

医渡科技 3 月通讯 | 2024 年

Yidu Tech Events in March 2024

集团亮点

Business Update

医渡科技重磅亮相华为中国合作伙伴大会

Yidu Tech Makes a Significant Appearance at Huawei China Partner Conference 2024

以“因聚而生 数智有为”为主题的“华为中国合作伙伴大会 2024”在深圳隆重举行。医渡科技作为华为在医疗领域的深度合作伙伴受邀出席本次大会，不仅带来了“医疗垂域大模型开启医疗智能化新篇章”主题演讲，更与华为联合发布疾控监测预警与应急指挥、医疗大模型一体机等多个智能化解决方案。医渡科技大模型的应用服务能力及软硬一体创新成果亦在本次大会上一站式演示呈现，吸引了众多行业伙伴和观众驻足体验。

The Huawei China Partner Conference 2024, themed "Born of Gathering, Digital Intelligence Is Promising," was held with grandeur in Shenzhen. Yidu Tech, as a deep partner of Huawei in the healthcare sector, was invited to attend. The company not only delivered a keynote on "Initiating a New Chapter in Healthcare Intelligence with Large Language Models (LLMs) in the medical vertical field" but also jointly launched multiple intelligent solutions with Huawei, including disease control monitoring and early warning, emergency command, and the LLM training and inference integrated machine. Yidu Tech's application service capabilities and integrated software and hardware innovations were showcased in a one-stop demonstration, attracting numerous industry partners and spectators to stop and experience.



医渡科技大模型获昇腾技术认证，共启昇腾原生开发

Yidu Tech's Large Language Model Receives Ascend Technology Certification, Kickstarting Native Development with Ascend

医渡科技的医疗行业大模型已经完成并通过了与昇腾的兼容性测试认证，在功能、性能与兼容性等各方面表现出色，可充分满足相关行业安全性、可靠性、稳定性的应用需求。华为中国合作伙伴大会上，医渡科技还成为首批启动昇腾原生开发的医疗智能企业，体现了华为对医渡科技创新与成果转化能力的高度认可。双方将在昇腾生态建设、医疗智能化创新、医疗 AI 原生应用开发等多个领域展开合作，共建、共享繁荣的医疗智能产业生态，加速推动医疗行业转型升级。

Yidu Tech's LLM in the medical vertical field has completed and passed the compatibility test certification with Ascend, demonstrating excellent functionality, performance, and compatibility. It fully meets the application needs of the industry in terms of safety, reliability, and stability. At the Huawei China Partner Conference, Yidu Tech became one of the first companies to initiate native development with Ascend,

reflecting Huawei's high recognition of Yidu Tech's innovation and capacity for transformational achievements. The two parties will cooperate in areas such as Ascend ecosystem construction, healthcare intelligence innovation, and native development of medical AI applications, to jointly build and share a prosperous intelligent medical industry ecosystem, and accelerate the transformation and upgrade of the healthcare industry.



医渡科技亮相 2024CMAC，生命科学主题沙龙成功举办

Yidu Tech Shines at the 2024 CMAC, Successfully Hosting the Life Sciences Themed Salon

中国（苏州）创新药物医学大会暨 2024CMAC 年会召开。期间，医渡科技旗下开心生活科技（HLT）成功举办了“数据实践一小时速览：新药生命周期管理中决策优化与效率提升”主题沙龙，深度探讨了真实世界数据在新药研发全生命周期驱动作用。同时 HLT 真实世界证据解决方案、CRO 解决方案等产品及服务重磅亮相本次会议，众多参会嘉宾莅临展台参观洽谈。医渡科技旗下医渡云技术创新副总裁、AI 架构师李林峰博士在“RWE 应用场景考量及医学价值再评价”分论坛发表了“临床科研平台助力真实世界研究高

效开展”主题报告，HLT 真实世界研究和药物经济学高级总监谢丽博士参与多元化医学人才发展路径案例分享与圆桌讨论。

The China (Suzhou) Innovative Medicine and Healthcare Conference, along with the 2024 CMAC annual meeting, took place. During the event, Happy Life Tech (HLT), a subsidiary of Yidu Tech, successfully held a salon on "A Quick Overview of Data Practice: Decision Optimization and Efficiency Improvement in New Drug Life Cycle Management," deeply exploring the driving role of real-world data throughout the entire life cycle of new drug development. HLT's solutions for real-world evidence, CRO services, and other products and services were prominently featured at the conference, attracting many attendees to visit and negotiate. Dr. Linfeng Li, Vice President of Technology Innovation and AI Architect at Yidu Cloud, a subsidiary of Yidu Tech, delivered a report on "Efficient Conduct of Real-World Studies with Clinical Research Platforms" at a forum on RWE application scenarios and medical value reevaluation. Dr. Li Xie, Senior Director of Real-World Studies and Pharmacoeconomics at HLT, participated in case sharing on diversified medical talent development paths and round-table discussions.



业务进展

Business Progress

医渡云中标南昌大学第一附属医院大数据一体化平台项目

Yidu Cloud Wins Bid for the Integrated Big Data Platform Project of the First Affiliated Hospital of Nanchang University

医渡科技旗下医渡云中标南昌大学第一附属医院的大数据一体化平台项目，项目金额为人民币 753.3 万元。

Yidu Cloud, a subsidiary of Yidu Tech, has won the bid for the integrated big data platform project of the First Affiliated Hospital of Nanchang University, with a project amount of 7.533 million RMB.

HLT 中标某国内知名药企一项医保准入项目

HLT Wins a National Renowned Pharmaceutical Company's Medical Insurance Access Project

本项目旨在帮助产品实现医保目录准入，提升产品市场竞争能力，HLT 将为其提供药物经济学与医保准入策略支持。HLT 集合了拥有丰富经验和专业知识的准入团队，挖掘产品价值档案、产出药物经济学模型（CEA&BIA）并组织开展专家调研与专家研讨会，助力企业产生医保准入证据，强化产品优势。

The project aims to help the product achieve medical insurance listing access, enhancing its market competitiveness. HLT will provide support in pharmacoeconomics and medical insurance access strategy, leveraging its access team with extensive experience and expertise to unearth product value archives, produce pharmacoeconomic models (CEA & BIA), and organize expert surveys and discussions to generate evidence for medical insurance access and strengthen

product advantages.

HLT 中标某生物医药企业 RWS 及 IV 期临床研究数统与系统项目

HLT Wins RWS and Phase IV Clinical Study Statistics and Systems Project for a Biopharmaceutical Company

该客户是一家专注于药物制剂创新研发的高科技生物医药企业，HLT 此次中标其上市后产品的真实世界研究及 IV 期临床研究数统和系统合作项目。此前，HLT 还曾中标该客户临床研究软件系统、DCT 医患平台建设、上呼吸道感染项目数统合作等多个项目。公司强大的产品功能和专业服务获得客户认可，因此再次赢得了客户复购。

The client, a high-tech biopharmaceutical company focusing on innovative drug formulation R&D, awarded HLT the project for real-world studies and statistics and systems cooperation for post-listing products, along with previous wins for clinical research software systems, DCT patient platforms, and upper respiratory infection project statistical cooperation. The company's strong product functionality and professional services have been recognized by the client, leading to repeat business.

HLT 以 DCT 平台赋能住友制药 III 期临床试验项目

HLT Empowers Sumitomo Pharma's Phase III Clinical Trial Project with DCT Platform

该研究是一项多中心、随机、双盲、安慰剂对照 III 期临床试验，旨在评价 Vibegron 相比安慰剂在中国膀胱过度活动症(OAB)受试者中治疗 12 周时在排尿次数方面的疗效。项目中，住友制药采用 HLT 因数智研远程智能临床试验数字化平台（DCT），实现了对受试者的远程访视与管理。值得关注的是，住友制药提报的“DCT 混合模式在中国注册三期临床研究中的实践应用”荣获“2023 年中国 DCT 实践十大案例奖”，HLT 与住友制药的合作不仅促进了 DCT 模式在中国注册三期临床试验中的实践应用，更为我国乃至全球范围内的临床试验领域树立了新的典范。



This study, a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial, aims to evaluate the efficacy of Vibegron compared to placebo in Chinese subjects with overactive bladder (OAB) over 12 weeks in terms of the number of urinations. Sumitomo Pharma utilized HLT's "CausaResearch" DCT platform for remote visits and management of participants. Notably, Sumitomo Pharma's submission on "Practical Application of DCT Hybrid Mode in China Registration Phase III Clinical Studies" won the "Top Ten DCT Practice Cases of 2023" award. The collaboration between HLT and Sumitomo Pharma not only promoted the practical application of the DCT model in China's registration of Phase III clinical trials but also set a new standard in the field of clinical trials both in China and globally.

集团荣誉

Honors of Yidu Tech

五连冠！医渡科技稳居医疗大数据企业排行榜首位

Five Consecutive Championships! Yidu Tech Tops the Medical Big Data Enterprise Ranking

“2023 医疗大数据企业排行榜”由中国科学院主管的权威媒体《互联网周刊》联合德本咨询、中国社会科学院信息化研究中心评选，每年发布一次。医渡科技连续 5 年登顶榜首，背后是其在医疗大数据领域综合创新实力和强应用落地能力的支撑，也是优势和壁垒的证明。

The "2023 Medical Big Data Enterprise Ranking" by the authoritative media "China Internet Week," which is under the administration of the Chinese Academy of Sciences, in collaboration with Deben Consulting (DBC) and CIS, is published annually. Yidu Tech has topped the list for five consecutive years, a testament to its comprehensive innovative strength and strong application capabilities in the field of medical big data,

as well as a demonstration of its advantages and barriers.

医渡科技斩获“金i奖”企业&解决方案双料奖

Yidu Tech Wins the "Golden i Award" for Both Enterprise & Solution

中国科学院旗下《互联网周刊》、德本咨询、中国社会科学院信息化研究中心与 eNet 研究院联合发布“2023 年度优秀服务商”评选结果。医渡科技凭借在医疗智能领域的持续创新和突出贡献，获评“2023 年度医疗智能企业”。同时，医渡科技打造的大模型训推一体解决方案荣获“2023 年度医疗解决方案”奖，展现了医渡科技在大模型时代的前瞻布局和强劲实力。

"China Internet Week," under the Chinese Academy of Sciences, Deben Consulting (DBC), CIS, and eNet Research Institute jointly announced the "2023 Excellent Service Provider" selection results. Yidu Tech, for its continuous innovation and outstanding contributions in the field of medical intelligence, was named "2023 Medical Intelligence Enterprise of the Year." At the same time, Yidu Tech's LLM training and inference integrated solution won the "2023 Medical Solution of the Year" award, showcasing Yidu Tech's forward-thinking layout and strong capabilities in the era of LLMs.



医渡科技大模型纳入 2024 中国“百模大战”竞争格局分析报告

Yidu Tech's Large Language Model Included in the 2024 China "Hundred Models Battle" Competitive Landscape Analysis Report

亿欧智库近日发布《2024 中国“百模大战”竞争格局分析报告》，分析“大战”爆发原因及核心竞争力，洞察垂类大模型的行业发展前景，探析“百模大战”的未来趋势。医渡科技作为医疗垂类大模型代表厂商获该报告收录，同时报告还将医渡科技大模型训推一体解决方案作为医疗行业重点案例，阐释分析了其突出优势及应用落地价值。

EO Intelligence recently released the "2024 China 'Hundred Models Battle' Competitive Landscape Analysis Report," analyzing the causes of the "battle" and core competitive strengths, insight into the industry development prospects of vertical LLMs, and exploring future trends of the "Hundred Models Battle." Yidu Tech, as a representative manufacturer of medical vertical LLMs, was included in the report, which also highlighted Yidu Tech's LLM training and inference integrated solution as a key case in the healthcare industry, elucidating its significant advantages and application value.

资本市场动态

IR Market Dynamics

中泰证券发布报告建议关注医渡科技

Zhongtai Securities Releases Report Recommending Attention to Yidu Tech

中泰证券发布《AI 应用：追本溯源之后，我们相信什么？》报告，指出人工智能新一轮十年级的技术和产业革命大幕已经拉开。GPT、Sora、Gemini 1.5、Claude 3 等基础模型能力持续迭代，各场景应用已经进入商业模式落地阶段，只需静待数据验证。关于投资方向，在医疗行业应用场景上，中泰证券建议关注医渡科技。



Zhongtai Securities published the report "AI Application: What Do We Believe After Tracing Back to the Origin?" highlighting that a new decade of technological and industrial revolution in artificial intelligence has commenced. With foundational models like GPT, Sora, Gemini 1.5, and Claude 3 continuously evolving and application scenarios entering the commercialization stage, the industry awaits data validation. Regarding investment directions, in the application scenarios of the medical industry, Zhongtai Securities recommends paying attention to Yidu Tech.

浙商证券发布报告提及医渡科技

Zheshang Securities Report Mentions Yidu Tech

浙商证券发布《遇上 AI 医疗——医药生物周跟踪 20240324》报告，报告指出近年来，多项政府文件将人工智能在医疗健康领域的应用写入发展规划，AI 医疗迎来发展利好。从整体规划来看，AI 医疗行业还将继续享受政策红利，政策将推动成果转化，加速 AI 医疗应用落地。其中 AI 精准医疗在国内的发展时间较短，整体发展向好，国内代表企业包括医渡科技等公司。

Zheshang Securities published the report "Encountering AI Healthcare - Biomedical Weekly Tracking 20240324," noting that in recent years, several government documents have incorporated the application of artificial intelligence in the medical and health fields into development plans, ushering in a favorable development environment for AI in healthcare. From an overall planning perspective, the AI healthcare industry will continue to enjoy policy dividends, with policies driving results transformation and accelerating the application of AI in healthcare. AI precision healthcare has a short development time in China but is progressing well, with representative companies including Yidu Tech among others.